EPHA2 and non-small cell lung carcinoma: Recently, the potential of CAR-T/NK cell therapy targeting erythropoietin-producing hepatocellular carcinoma A2 (EphA2) has been design as an effective treatment for NSCLC with high EphA2 expression [82].